免疫检查点阻断相关的皮肤不良反应：系统评价和荟萃分析。
Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis.
机构信息
Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
出版信息
Crit Rev Oncol Hematol. 2021 Jul;163:103376. doi: 10.1016/j.critrevonc.2021.103376. Epub 2021 Jun 2.
Dermatological toxicity is the most common immune-related adverse events (irAEs) following immune checkpoint inhibitors (ICIs). A better understanding of this side effect enables early recognition, diagnosis and management in clinical practice. We did a systematic review and meta-analysis of literature published on ClinicalTrials.gov, Pubmed, Embase, and Cochrane Library to assess the differences in cutaneous irAEs among ICIs, the effect from dosage and combined treatment on the incidence, and the predictive values for prognosis. A total of 46 eligible RCTs involving 28,569 patients were included. This study indicates that cutaneous irAEs are dose-independent and agent-specific immune reactions with the highest risk observed in CTLA-4 blockade and might not a surrogate prognostic indicator.
皮肤毒性是免疫检查点抑制剂（ICI）治疗后最常见的免疫相关不良事件（irAE）。更好地了解这种副作用可以使我们在临床实践中能够更早地识别、诊断和管理。我们对 ClinicalTrials.gov、Pubmed、Embase 和 Cochrane Library 上发表的文献进行了系统评价和荟萃分析，以评估 ICI 之间皮肤 irAE 的差异、剂量和联合治疗对发生率的影响，以及对预后的预测价值。共纳入了 46 项符合条件的 RCT，涉及 28569 例患者。这项研究表明，皮肤 irAE 是与剂量无关的、具有药物特异性的免疫反应，其中 CTLA-4 阻断的风险最高，可能不是预后的替代指标。
Zotero 插件